At ISSCR 2026, groundbreaking clinical data revealed the long-term survival of human neural progenitor cells transplanted into patients with retinitis pigmentosa (RP), marking a pivotal advance in retinal disease research. The study demonstrated that CNS10-NPC cells, derived from fetal brain cortex, survived in the subretinal space for at least one year without significant safety concerns, offering new hope for a disorder that currently lacks effective treatments.
Retinitis pigmentosa encompasses a diverse group of hereditary retinal conditions characterized by progressive vision loss. Due to the complexity of over a thousand genetic mutations causing RP, mutation-specific gene therapies have faced significant limitations. In contrast, cell-based approaches such as neural progenitor cell transplantation present a mutation-agnostic therapeutic strategy, potentially benefiting a wide patient population.
The Phase 1/2a clinical trial, supported by the California Institute for Regenerative Medicine (CIRM), involved 13 RP patients receiving either 300,000 or 1,000,000 CNS10-NPC cells via a single subretinal injection. Patients were monitored for 12 months, with subsequent enrollment in a long-term follow-up protocol. Remarkably, visual acuity remained stable throughout the observation period, while optical coherence tomography imaging confirmed sustained engraftment of the transplanted cells.
Adverse events were minimal, limited to isolated cases of epiretinal membrane formation and a single persistent subretinal bleb, reinforcing the favorable safety profile of CNS10-NPC transplantation. The persistence of these fetal-derived neural progenitors establishes an essential benchmark for future stem cell therapies targeting retinal degeneration.
Preclinical studies underpinning this trial indicated that CNS10-NPC cells exert neuroprotective effects by mitigating retinal inflammation and secreting trophic factors that support photoreceptor survival. While the trial’s one-year timeline was insufficient to observe functional vision improvements due to the slow progression of RP, ongoing follow-up aims to assess whether the grafted cells can decelerate disease advancement in the long term.
Significantly, the study heralds a gene-agnostic treatment paradigm, diverging from traditional gene therapies that target individual mutations. This approach could revolutionize management for patients with heterogeneous genetic causes of RP and other retinal dystrophies.
In addition to the fetal-derived cell product, data were also presented on an induced pluripotent stem cell (iPSC)-derived neural progenitor therapy. The iPSC platform offers promise for scalable manufacturing and broader patient access while circumventing ethical issues associated with fetal tissue sources.
The demonstration of sustained cell survival and safety in human subjects lays a critical foundation for the next generation of regenerative treatments aimed at preserving vision. As researchers continue to monitor RP patients receiving CNS10-NPC transplants, optimism grows that such cell-based therapies may one day halt or even reverse the relentless decline in sight that afflicts millions worldwide.
Subject of Research: Human neural progenitor cell transplantation for retinitis pigmentosa
Article Title: Long-term Survival of Transplanted Neural Progenitors Demonstrated in Retinitis Pigmentosa Patients
News Publication Date: 2026
Web References: www.isscr2026.org
Keywords: Retinitis pigmentosa, neural progenitor cells, stem cell therapy, retinal degeneration, gene-agnostic treatment, CNS10-NPC, induced pluripotent stem cells
